Effect of omeprazole on the steady-state pharmacokinetics of voriconazole

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 56-61

  Wood, Nolan ^a   Tan, Keith ^a   Purkins, Lynn ^a   Layton, Gary ^a   Hamlin, Julia ^a   Kleinermans, Diane ^a,b   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Interaction; Omeprazole; Pharmacokinetics; Safety; Toleration; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 3A4; OMEPRAZOLE; PROTON PUMP INHIBITOR; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; DUODENUM ULCER; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STOMACH ULCER; VISUAL DISORDER; VISUAL IMPAIRMENT;

EID: 0344512410     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02000.x     Document Type: Article

References (22)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F79, September 1995.
10. 450 2C19. Clin Pharmacokinet 1995; 29 (Suppl. 1): 45-52.
11. Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958.
12. Physicians' desk reference, 52nd edn. Montvale, NJ: Medical Economics Group, Inc., 1998; 528-532.
13. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
14. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism Disposition 1997; 25: 853-862.
15. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12 (Suppl. 2): S54-S63.
16. Birkett DJ, Andersson T, Miners JO. Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. In Method enzymology cytochrome P450, Part B, 272, eds Johnson EF, Waterman MR. San Diego: Academic Press, 1996; 132-139.
17. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
18. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62: 384-391.
19. Height and Weight Standards. New York: Metropolitan Life Insurance Co., 1993.
20. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
21. SAS/STAT User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
22. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553.